Taylor Frigon Capital Management LLC Has $3.75 Million Stock Position in Glaukos Co. (NYSE:GKOS)

Taylor Frigon Capital Management LLC lowered its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 10.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 25,012 shares of the medical instruments supplier's stock after selling 3,010 shares during the period. Glaukos accounts for approximately 1.9% of Taylor Frigon Capital Management LLC's holdings, making the stock its 9th largest position. Taylor Frigon Capital Management LLC's holdings in Glaukos were worth $3,750,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of GKOS. Louisiana State Employees Retirement System lifted its position in Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after acquiring an additional 100 shares during the last quarter. Handelsbanken Fonder AB lifted its position in Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock worth $2,204,000 after acquiring an additional 100 shares during the last quarter. HighTower Advisors LLC lifted its position in Glaukos by 3.3% during the third quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier's stock worth $416,000 after acquiring an additional 103 shares during the last quarter. New York State Teachers Retirement System lifted its position in Glaukos by 0.4% during the third quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier's stock worth $6,272,000 after acquiring an additional 200 shares during the last quarter. Finally, KBC Group NV lifted its position in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after acquiring an additional 201 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Remove Ads

Glaukos Price Performance

GKOS traded up $1.54 during trading on Friday, hitting $119.87. 610,751 shares of the stock traded hands, compared to its average volume of 733,191. Glaukos Co. has a twelve month low of $83.90 and a twelve month high of $163.71. The company has a market cap of $6.61 billion, a price-to-earnings ratio of -41.77 and a beta of 1.04. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The business has a 50 day moving average price of $150.22 and a 200 day moving average price of $139.30.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities research analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company's stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GKOS. Wells Fargo & Company raised their price objective on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Morgan Stanley downgraded shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price target for the company. in a research report on Monday, December 2nd. JPMorgan Chase & Co. lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Stifel Nicolaus lifted their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. Finally, BTIG Research lifted their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.